Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 5:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,834 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Autoimmune/Connective Tissue Diseases Clear all
Completed Phase 2 Interventional

Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)

NCT00326339
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
R788, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
27
States / cities
Santa Maria, California • Ocala, Florida • Orange Park, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2009 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Early Phase 1 Interventional

Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis

NCT02052167
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
methotrexate prefilled pen
Device
Lead sponsor
medac GmbH
Industry
Eligibility
2 Years to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 1, 2026, 5:43 PM EDT
Terminated Not applicable Interventional

The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis

NCT02078375
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Protein, Carbohydrate (Placebo), Resistance Exercise Program
Dietary Supplement · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 95 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Oct 1, 2026, 5:43 PM EDT
Active, not recruiting Phase 3 Interventional

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus

NCT05648500
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Cenerimod, Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Huntington Park, California • Aurora, Colorado • Clearwater, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Active, not recruiting Not applicable Interventional

Zimmer Trabecular Metal Total Ankle PMCF

NCT02038140
View directory record Official record
Conditions
Degenerative Arthritis, Rheumatoid Arthritis, Post Traumatic Arthritis
Interventions
Zimmer Trabecular Metal Total Ankle System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
5
States / cities
Sacramento, California • Grand Rapids, Michigan • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis

NCT00001885
View directory record Official record
Conditions
Healthy, Pulmonary Fibrosis, Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

NCT01597050
View directory record Official record
Conditions
Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic
Interventions
R932333, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting Not applicable Interventional

ConsideRAte Study - Splenic Stimulation for RA

NCT05003310
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Active Stimulation, Sham Stimulation, Baricitinib, Background Treatment
Device · Drug
Lead sponsor
Galvani Bioelectronics
Industry
Eligibility
22 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
12
States / cities
Anniston, Alabama • Covina, California • Whittier, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Collection and Distribution of Biospecimens for Novel Research Uses

NCT03848962
View directory record Official record
Conditions
Cancer, Healthy, Gastrointestinal Complication, Autoimmune Diseases, Infectious Disease, Women's Health: High-Risk Pregnancy, Dermatologic Disease, Blood Disease
Interventions
Not listed
Lead sponsor
iSpecimen Inc
Industry
Eligibility
1 Month to 89 Years
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Huntsville, Alabama • Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs)

NCT00891020
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tocilizumab [RoActemra/Actemra], Nonbiologic DMARDs of investigator's choice
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
886 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
227
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 201 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2012 · Synced Oct 1, 2026, 5:43 PM EDT
Active, not recruiting Phase 2 Interventional

Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA

NCT06868290
View directory record Official record
Conditions
ANCA Associated Vasculitis (AAV)
Interventions
Rapcabtagene autoleucel, Active Comparator, Glucocorticoids
Biological · Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
14
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Completed No phase listed Observational

Cup Position in THA With Standard Instruments

NCT03189303
View directory record Official record
Conditions
Osteoarthritis; Rheumatoid Arthritis; Post Traumatic Arthritis
Interventions
Primary Uncemented Total Hip Arthroplasty
Device
Lead sponsor
DePuy Orthopaedics
Industry
Eligibility
21 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
5
States / cities
Grand Rapids, Michigan • New York, New York • Gastonia, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections

NCT02150070
View directory record Official record
Conditions
Pharmacokinetics of ASP2408, Healthy Subjects
Interventions
ASP2408, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 1, 2026, 5:43 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

NCT05946941
View directory record Official record
Conditions
Sjögren's Syndrome
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
28
States / cities
Fullerton, California • La Palma, California • San Francisco, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Not applicable Interventional

Improving Motivation for Physical Activity in Arthritis Clinical Trial

NCT00248105
View directory record Official record
Conditions
Osteoarthritis, Knee, Rheumatoid Arthritis
Interventions
Lifestyle Physical Activity Management
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
889 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 2Phase 3 Interventional

Lab Study of MQX-503 in Treatment of Raynaud's

NCT00253331
View directory record Official record
Conditions
Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
Interventions
topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 3 Interventional Results available

A Study in Moderate to Severe Rheumatoid Arthritis Participants

NCT01721057
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Placebo, Baricitinib, cDMARD
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
48
States / cities
Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2019 · Synced Oct 1, 2026, 5:43 PM EDT
Completed No phase listed Observational

Analysis of B Cells From Autoimmune Individuals

NCT02747277
View directory record Official record
Conditions
Lupus Erythematosus, Rheumatoid Arthritis, Type 1 Diabetes
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Not applicable Interventional Results available

Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial

NCT04776161
View directory record Official record
Conditions
Rheumatic Diseases, Gout, Adherence, Medication, Lupus Erythematosus, Systemic
Interventions
Cue-Reward Intervention, Cue-Reward Intervention with possible intensification
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 1, 2026, 5:43 PM EDT
Completed Phase 2 Interventional

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis

NCT01626573
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Itacitinib, Itacitinib Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
17
States / cities
Palm Desert, California • Pasadena, California • Lake Mary, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment

NCT02253251
View directory record Official record
Conditions
Cancer
Interventions
KRAS-variant and microRNA binding site mutation testing
Genetic
Lead sponsor
MiraKind
Other
Eligibility
18 Years and older
Enrollment
15,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2035
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2025 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions

NCT04684602
View directory record Official record
Conditions
Autoimmune Diseases, Cardiovascular Disorders, Diabetes Complications, Integumentary Disease, Musculoskeletal Disorders, Neurodegenerative Disorders, Neurologic Disorders, Pulmonary Disorders, Sexual Dysfunction, Urologic Disorders, Viral Illness
Interventions
PrimePro™/ PrimeMSK™
Biological
Lead sponsor
Thomas Advanced Medical LLC
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 1, 2026, 5:43 PM EDT
Active, not recruiting Not applicable Interventional

Persona Ti-Nidium Post-Market Clinical Follow-up

NCT04817969
View directory record Official record
Conditions
Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of the Knee, Avascular Necrosis, Patellofemoral Osteoarthritis
Interventions
Zimmer Biomet Persona Ti-Nidium Total Knee System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
7
States / cities
Parker, Colorado • Hyattsville, Maryland • Jackson, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 1, 2026, 5:43 PM EDT
Recruiting Phase 3 Interventional

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).

NCT06133972
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, Ianalumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
25
States / cities
Anniston, Alabama • Burbank, California • La Palma, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 1, 2026, 5:43 PM EDT